The authors regret that there are errors in Fig. 1, panel d , on the published manuscript. By mistake, the legend and description incorrectly state that the samples analysed are from a Stage 4 subset of the dataset GSE45547, when they correspond to the whole dataset. Consequently, label on (i) is incorrect. In addition, there is a typo mistake in the p value stated in the same panel which should be corrected to 0.048. The indicated p value is the result of applying the logrank test, not bonferroni. The corrected Figure and legend are shown below. The description written in the manuscript corresponding to the results presented in this figure should take into consideration these changes. These errors and corrections do not change the scientific conclusions of the article.
The authors would like to apologize for this error and any inconvenience this may have caused.
The authors would also like to clarify the statistical methodology used for the classification of patients in the survival analysis. A more detailed Statistical analysis section, covering this analysis, is provided as supplementary material.
The authors would like to further clarify that our data do not support that CD44 expression does have prognostic value by itself. The aim of the work is the description and characterization of a population of CD44 high expressing cells and their contribution to malignancy, and not to stablish CD44 as a biomarker to be used for prognosis as a single molecule. In fact, the authors discuss the difficulties presented by the expression of CD44 in different cell populations in neuroblastoma. The authors suggest to continue exploring the potential future use of this marker in combination with others, some of which are described. 
